anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will undergo a Schroth method-based virtual reality exercise program under the supervision of a physiotherapist, 2 days a week for 12 weeks, and 1 day a week for the next 12 weeks, for a total of 36 sessions. Participants will be given a home exercise program to do on the days they do not come to the session, and will be asked whether they have done it or not when they come to each session. Schroth method based virtual reality exercise program will be made on Nintendo Wii. Games within Nintendo Wii will be implemented in individually configured positions in accordance with the Schroth method.The virtual reality exercise program will be divided into 4 phases: 0-4, 5-8, 9-12, 12-24. Sessions will last 40 minutes in total, including 5 minutes of warm-up, 30 minutes of balance and sports games, and 5 minutes of cool-down. Progression will be made by difficulty level and positional in all games.
PROBLEM TO BE SOLVED: To obtain a new compound useful for suppressing of atherosclerosis and coronary cardiac disease caused from increase of cholesterol, etc., by substituting with a heterocycle. SOLUTION: This phenylglycinolamide substituted with a heterocycle expressed by the formula I [A is quinolyl or expressed by the formula II (R<3> and R<4> are each H or phenyl, etc.; R<5> is phenyl or alkylthio, etc.); R<1> is a 3-8C alkyl, etc.; R<2> is expressed by the formula III (R<13> is expressed by the formula CH2 -OH; R<14> is hydroxyl, a halogen, etc.)] and its salt are selected as the objective compound. The compound of the formula I is produced by reacting a carboxylic acid of the formula IV with an amine of the formula H2 N-R<2> in an inert solvent in the presence of a base and/or an auxiliary. The inert solvent is e.g. ethers or a halogenated hydrocarbon, etc.  Preferably, the base is an alkali metal hydroxide and 1-5mol of the base is used to 1mol of the compound of the formula IV, and the reaction temperature is usually within a range of 0-150 deg.C, and the pressure is a normal pressure. A dehydrating agent is suitable as the auxiliary and the using amount is 0.5-3mol.
Laryngoscopy for intubation or less invasive surfactant administration (LISA) in neonates is a stressful and painful procedure that necessitates a sedo-analgesia except in the case of an immediate life-threatening emergency. Nevertheless, there are discrepancies in premedication practices amongst neonatal units. In order to optimize analgesia before laryngoscopy in neonates, the French neonatal society issued best practice guidelines in January 2023 for premedication before laryngoscopy in neonates. These guidelines were published in an English peer-reviewed journal and presented in national conferences. However, the implementation of new premedication protocols in neonatal units can be made difficult due to local habits, poor dissemination of the guidelines and a limited level of evidence on some premedication agents. Thus, conducting a survey one year after issuing the best practice guidelines on premedication seems important to evaluate French premedication practices and to evaluate the impact and dissemination of the guidelines
The purpose of this study is to investigate the usefulness of infusing purified CD34+ cells of donor origin in order to augment graft function in response to declining chimerism after initially performing an allogeneic hematopoietic stem cell transplant (HSCT) for children with primary immunodeficiency diseases. This protocol will be utilized for patients with waning mixed donor chimerism that is inadequate for correction of clinical condition or disease for which stem cell transplant was performed, or for augmentation of immune function. An infusion of selected CD34+ stem cells will be given without any preparative regimen. As the children eligible for this protocol have reduced immune function and pre-existing donor chimerism, we hypothesize that stem cells will be able to engraft and the infusion will augment graft function. This therapy serves as an alternative to a second stem cell transplant that is known to be associated with significant morbidity and mortality. CD34+ stem cells will be collected from the donor used for initial stem cell transplant. Cells will be T-cell depleted (TCD) by performing a CD34 selection using the CliniMACS device (Miltenyi Biotec) in order to prevent development of new or exacerbation of existing graft versus host disease (GVHD), as avoidance of GVHD in nonmalignant diseases is desirable. There is sufficient data showing that mixed donor chimerism is adequate for reverting disease phenotype in certain primary immunodeficiencies. Observations from Europe and CCHMC show that donor chimerism might be boosted by CD34+ stem cell infusion alone without any specific preparative regimen. This therapy is likely to be associated with low toxicity due to the absence of a preparative regimen and lack of exposure to fresh donor cells capable of initiating GVHD, and offers potential significant benefit.
Gastropericardial fistula is a rare, extremely serious and life-threatening condition. Its most common aetiology is secondary to iatrogenic injury following gastric surgery. Clinical manifestations may be non-specific with precordial pain, simulating an acute coronary syndrome, and may be accompanied by electrocardiogram abnormalities. Diagnosis is made by thoracoabdominal computed tomography (CT) with oral and intravenous contrast. Treatment is surgical and consists of repair of the anomalous communication. We present the case of an 81-year-old male patient with gastropericardial fistula who underwent surgery, with the aim of reviewing the diagnosis and the appropriate therapeutic strategy.
The use of a 17 alpha-acyloxy-6-methyl pregna-4,6-dien-3,20 dione (I) in which the acyl group has up to 10C atoms, as a therapeutic agent for oral or parenteral admin. to patients or animals who have undergone mastectomy following breast cancer, is new. The admin. is continued until there is no further risk of matastatic transmission or recurrence of the cancer. Better activity than known therapeutic agents, and absence of toxicity. (I) is preferably given as soon after the mastectomy as possible, and it is continued for 2-5 years. The daily dosage is 40-800 mg preferably 160-320 mg, given in 2-8 doses, pref. 4. (I) may be given with other active components, such as digitalin, insulin, non-steroidal anti-inflammatories, and analgesics.
PURPOSE: The management of renal masses in the elderly population is particularly challenging, as these patients are often more frail and potentially more susceptible to surgical morbidity. This review aims to provide a comprehensive analysis of the outcomes of partial nephrectomy (PN) for treating renal masses in elderly individuals.
METHODS: A systematic electronic literature search was conducted in May 2024 using the Medline (via PubMed) database by searching publications up to April 2024. The population, intervention, comparator, and outcome (PICO) model defined study eligibility. Studies were deemed eligible if assessing elderly patients (aged 70 years or older) (P) undergoing PN (I) with or without comparison between a different population (non-elderly) or a different treatment option (radical nephrectomy, ablation or active surveillance) (C) evaluating surgical, functional, and oncological outcomes (O).
RESULTS: A total of 23 retrospective studies investigating the role of PN in elderly patients were finally included. PN emerged as a safe procedure also for older patients, demonstrating good outcomes. Preoperative evaluation of frailty status emerged to be paramount. Age alone was discredited as the sole reason to reject the use of PN. The main limitation is the retrospective nature of included studies and the lack of the assessment of elderly patients' frailty.
CONCLUSIONS: The surgical treatment of renal masses in older patients is a challenging scenario. PN should be chosen over RN whenever possible since it can better preserve renal function. The use of minimally invasive techniques should be favored in this extremely fragile group of patients.
When used in an external insulin pump for subcutaneous infusion, HUMALOG should not be diluted or mixed with any other insulin. Change the HUMALOG in the reservoir at least every 7 days, change the infusion sets and the infusion set insertion site at least every 3 days. HUMALOG should not be exposed to temperatures greater than 98.6°F (37°C). 

Malfunction of the insulin pump or infusion set or insulin degradation can rapidly lead to hyperglycemia and ketosis. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Interim subcutaneous injections with HUMALOG may be required. Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure [see Dosage and Administration (2.3), How Supplied/Storage and Handling (16), and Patient Counseling Information (17.2)].
Person-centered occupational therapy intervention was applied to both groups according to the evaluation results. The basis of the person-centered occupational therapy intervention is the activities and visual skills that the participants stated in the COPM in the first evaluation and in which they had problems. Person-centered occupational therapy intervention consists of 5 stages: (1) person-centered goal setting, (2) creation of the therapy plan, (3) implementation of interventions, (4) evaluation of results, and (5) obtaining feedback.
Introduction: Obesity is associated with numerous chronic conditions and an increased risk for surgical complications. Laparoscopic and robotic adrenalectomy have proven effective in the resection of adrenal tumors. This study analyzes the outcomes of severely obese patients (body-mass index [BMI] ≥35 kg/m2) following minimally invasive adrenalectomy. Materials and Methods: A retrospective analysis of patients who underwent minimally invasive adrenalectomy at our institution between 2010 and 2023 was conducted. Two matching analyses were performed. The first analysis compared patients with BMI greater versus lower than 35 kg/m2. The second analysis compared outcomes between robotic and laparoscopic adrenalectomy in patients with a BMI ≥35 kg/m2. Results: A total of 278 patients were included in the study. The median tumor size was 29 mm. Adrenal tumors had similar laterality, and most were hormonally active (66.2%). The most common pathological diagnosis was pheochromocytoma (25.5%). No statistical difference was found in peri- and postoperative outcomes between patients with BMI ≥35 and <35 kg/m2 who underwent minimally invasive adrenalectomy. When the surgical approach was compared in severely obese patients, robotic adrenalectomy was associated with shorter hospital length of stay with similar operative time as the laparoscopic approach. Conclusions: Minimally invasive adrenalectomy is safe and feasible in patients with BMI ≥35 kg/m2. Robotic and laparoscopic approaches are both safe and efficient for the resection of adrenal tumors in severely obese patients.
247,018. Wal, A. van der. Feb. 28, 1925. Lotions; medicaments for external application. -A remedy for foot and mouth disease consists essentially of a solution made by dissolving sugar of lead (lead acetate) and litharge in hot water and adding a solution of alum in water, the proportions being such as to leave an excess of a lead compound in solution. Disinfectants, medicinal tinctures, and insect-repalling substances may be added. Specified additional ingredients of these kinds are :-boracic, :benzoic, and salicylic acids, tinctures of myrrh, aloes, and eucalyptus, and oils of eucalyptus and citronella. Colouring matter such as burnt chicory or caramel may also be added. A mixture which will adhere to the hoofs consists of the solution referred to above together with wood tar, resin, a vegetable fatty oil, bees' wax, yolk (grease), zinc oxide, boric, benzoic or salicyclio acid, and eucalyptus or citronella oil or both.
Chronic headache is a serious clinical problem in women which psychological factors play major role and requires an approach with bio-psycho-social integrity. Psychiatric comorbidities such as anxiety disorder and major depression are frequent. Young described Early Maladaptive Schemas (EMS) as maladaptive and dysfunctional patterns that appear due to unpleasant situations occurred between patient and people who were important to him. EMS affect perception, emotions, thoughts and behaviors that makes a basis for many disorders. EMS are found to be related with depression, anxiety and somatization within recent literature. In literature, chronic pain and migraine's relationship with EMS were studied before in a few separate articles. However, there is a lack of data that compares the relationship between EMS and clearly distinguished headache types: migraine (MH) and tension-type headache (TTH) especially in female patients who are more prone to somatic complaints/findings. Our study directly compared three groups, migraine and tension type headache and healthy controls. 150 female patients with chronic headache were enrolled for study in consecutive fashion. Exclusion criteria were as follows: age < 18 or > 60 years, male gender, existence of comorbidity affecting central nervous system, headache due to drug/substance abuse, previous diagnosis of migraine with aura, previous diagnosis of psychotic disease, mental retardation, cognitive disorders, being in delirium state. Patients were grouped into two categories according to type of headache and a third control group. All patients were evaluated with Young Schema Questionnaire (YSQ) and their scores were noted and categorized in related schema domains. Sociodemographic data were comparable among groups. However, there were significant differences in terms of previous psychiatric diagnosis and psychiatric drug usage. When we compared YSQ scores, groups differed in many schema categories. MH group showed significantly higher scores in dependency/incompetency, unrelenting standards and punitiveness schemas when compared to remaining two groups. TTH group had significantly more points in emotional deprivation, vulnerability to harm or illness schemas among all groups. On the other hand, control group had significantly higher scores in insufficient self-discipline and entitlement/grandiosity schemas when compared to both MH and TTH groups. Presence of EMS in female patients with headache significantly differed from control group. Types of EMS were also significantly different between patients with MH and TTH among this whole headache group. We suggest that a comprehensive psychotherapeutic approach that targets to improve coping methods for distinct EMS in distinct headache types would provide critical aid to general treatment of headaches especially in resistant cases.
Infants in this group were repositioned "every hour" based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours.
FIELD: medicine, therapy. SUBSTANCE: the present innovation could be applied for curative-prophylactic purposes in medical establishments for treating pain syndrome in patients with chronic somatic diseases. One should perorally introduce trifluopyrazine at 2.5 mg/once daily for 1 mo. Then comes psychorelaxation therapy at biological feedback of 10-15 min duration 3-5 times weekly, 8-10 exercises totally. This method enables to decrease the dosage of neuroleptic and simultaneously decrease side effects of preparation mentioned. EFFECT: higher efficiency of therapy. 2 ex
Systems, methods, and storage media for providing an interface for textual editing through speech are disclosed. One aspect of the disclosure may include storing a narrative textual message and presenting the narrative textual message via a client computing platform. Speech uttered by a user may be received. Speech recognition may be performed on the speech to determine words spoken by the user. The words determined from the speech may be analyzed to detect whether an editing command was spoken. The editing command may include a parameter and an edited value for the parameter. The editing command may be processed to insert the edited value for the parameter or replace an initial value to the parameter with the edited value. Information may be transmitted to the client computing platform that causes the narrative textual message to be visually presented including edits based on the editing command.
NNZ-2566 reconstituted in Lemon flavoured cordial and Water for Injection. 6/8 subjects in each cohort (3 cohorts in total) to receive NNZ-2566 experimental treatment.
The invention relates to the use of neopentyl glycol diisononanoate (CAS No. 27841-07-2) as a fixative for perfume oils or as a fixative for (top note) fragrance substances. The invention also relates to certain compositions containing neopentyl glycol diisononanoate and one or more top note fragrance substances. Furthermore, the invention relates to a method for producing such compositions and (cosmetic) products containing a composition according to the invention. Additionally the invention relates to a method for imparting, intensifying or modifying an odor on the (human) skin. A particular aspect of the present invention relates to the improved adherence of volatile fragrance substances to (human) skin and/or (human) hair. Apart from this the invention relates to a combination (kit) comprising neopentyl glycol diisononanoate and one or more top note fragrance substances.
This study includes the implementation and evaluation of a culturally- and contextually-adapted intervention package based on the Kaiser Permanente Northern California and World Health Organization HEARTS programs for hypertension diagnosis and treatment at primary health centers in Abuja, Nigeria. The intervention has been adapted based on a local needs' assessment including evidence synthesis and specific exploration of health care workers' knowledge, attitudes, and behaviors related to hypertension, causes, consequences, and treatment, including fixed-dose combination and patient self-management, and patients' knowledge, attitudes, and behaviors related to hypertension, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable system- and patient-level barriers to hypertension treatment and control across capability, intentional, and system domains using the Consolidated Framework for Implementation Research. Preparedness and capacity have been assessed at primary health centers (e.g. available staff; information systems; use of clinical guidelines) through an adapted Service Availability and Readiness Assessment (SARA) instrument during the formative work for this study. The multi-level implementation package includes: 1) patient registration and empanelment (health system level), 2) standard treatment protocol (national policy level), 3) encouragement of fixed-dose combination therapy (health system level), 4) team-based care (health worker level), and 5) home blood pressure monitoring and health coaching (patient-level).
PROBLEM TO BE SOLVED: To enable the regulation of the growth of body hair and/or hair of the head by containing a lipoxygenases inhibitor and a cyclooxygenase inhibitor therein. SOLUTION: This composition for medicines or cosmetics is prepared by containing 0.01-5wt.% lipoxygenase inhibitor and 0.001-5wt.% cyclooxygenase inhibitor therein. The lipoxygenase inhibitor is selected from a redox inhibitor or a nonredox inhibitor, a precursor of the redox inhibitor, an iron chelating agent, an imidazole-containing compound, phenothiazine, a benzopyran derivative and certain kinds of eicosanoids. The cyclooxygenase inhibitor is selected from especially a nonsteroidal antiinflammatory agent, e.g. an arylcarboxyl derivative, a pyrazole-containing derivative, an oxicam derivative and a nicotinic acid derivative. The composition can be used for effectively inhibiting and/or delaying the growth of body hair and/or hair of the head or promoting the depilation of the body hair and/or hair of the head without manifesting the toxicity or adverse effects.
The study will consist of a Pre-Treatment Phase into which subjects potentially eligible for the Treatment Phase will be recruited. Subjects will remain in the Pre-Treatment Phase until they experience respiratory virus symptoms at which time they will be further screened for eligibility for entry into the Treatment Phase. If eligible, subjects will be randomised 1:1 to receive SNG001 or placebo once daily for 14 days. Doses will be delivered by a CE marked breath actuated nebuliser (I-neb Philips Respironics). Subjects will be assessed for changes in changes in respiratory virus symptoms and asthma symptoms at home using a text message system, and via telephone questionnaire. Lung function will be measured both at home by the subjects (PEFR only) and in the clinic. Efficacy and safety will be monitored until at least 30 days post treatment.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to pharmaceutical industry, in particular, to preventive anti-stress medication. Preventive anti-stress medication for prevention of fatigue induced by stress with continuous physical and psychic load, containing chlorogenic acids or their pharmaceutically acceptable salts as active ingredients. Medication for prevention of central fatigue, syndrome of central fatigue or overstrain. Application of chlorogenic acids or their pharmaceutically acceptable salts in production of preventive anti-stress medication. Application of chlorogenic acids or their pharmaceutically acceptable salts in production of medication for prevention of central fatigue, syndrome of central fatigue or overstrain. ^ EFFECT: inventions efficiently prevent and reduce fatigue, induced by stress with continuous physical and psychic load. ^ 11 cl, 2 dwg, 2 ex
During the study, subjects diagnosed as community-acquired pneumonia in children according to "Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version)" will be assigned to the Huashibaidu group and the placebo group. Then they will receive 5 days treatment, prescribed by investigator according to study design. At the same time, they will finish a series of examinations, including biomarkers associated with infection, screening of pathogen, imaging examination and tNGS.
In the SOC group patients received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, when INR was higher than 1.8. They received platelets at the amount of 1 apheresis Unit, when platelets count was lower than 50000/μl.